{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-046197","form_type":"8-K","ticker":"LXEO","cik":"0001907108","company_name":"Lexeo Therapeutics, Inc.","filed_at":"2024-04-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.175656+00:00","generated_at":"2026-06-03T14:32:10.123223+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Lexeo Therapeutics licenses full data and IP for LX2006 FA cardiomyopathy gene therapy from Cornell","bullets":["Upfront fees total $600,000; potential regulatory milestones up to $2.1M and commercial milestones up to $100M.","Exclusive license to patent rights and non-exclusive know-how for AAVrh.10hFXN (LX2006), including right to reference IND.","11 participants dosed across two trials (Lexeo's SUNRISE-FA and Weill Cornell Phase 1A); no treatment-related SAEs reported.","Interim clinical data readout expected mid-2024, combining data from both studies with up to 18-month follow-up.","LX2006 has FDA Orphan Drug, Rare Pediatric Disease, and Fast Track designations for FA cardiomyopathy."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-046197","json":"https://secwatch.observer/filing/0000950170-24-046197.json","markdown":"https://secwatch.observer/filing/0000950170-24-046197.md","text":"https://secwatch.observer/filing/0000950170-24-046197.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1907108/000095017024046197/0000950170-24-046197-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1907108/000095017024046197/lxeo-20240422.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T14:32:10.123223+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f980000ac5d87db5d1f88e0fb1a096e1ee619413","claim":"Lexeo Therapeutics, Inc. entered into Third License Agreement with Cornell University valued at $600,000 (effective 2024-04-21).","evidence_excerpt":"On April 21, 2024, Lexeo Therapeutics, Inc. (the “Company”) entered into the Third License Agreement (the “License Agreement”) with Cornell University","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1907108/000095017024046197/0000950170-24-046197-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Cornell University"},{"label":"Value","value":"$600,000"},{"label":"Effective","value":"2024-04-21"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}